Start ENTRESTO® with confidence
ENTRESTO is available in 3 dosage strengths1
Pills shown not actual size.
Pills shown not actual size.
Choose initial dose of ENTRESTO based on current treatment and titrate to the target dose1
ENTRESTO is contraindicated with concomitant use of an ACEi and in patients with a history of angioedema related to previous ACEi or ARB therapy1
Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan1
Unless your patient is on a high ACEi/ARB dose, start ENTRESTO at 24/26 mg twice daily and double the dose every 2 to 4 weeks, as tolerated by the patient. When switching from an ACEi, be sure to allow for a 36-hour washout period prior to initiating ENTRESTO.1 |
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1
BOXED WARNING: FETAL TOXICITY
ENTRESTO is contraindicated in patients with hypersensitivity to any component...
ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
LVEF is a variable measure, so use clinical judgment in deciding whom to treat.
Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin ‖ receptor blocker; LAE, left atrial enlargement; LVH, left ventricular hypertrophy.
References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193-1202. doi:10.1002/ejhf.548